B. Riley Raises Earnings Estimates for Tango Therapeutics

Key Points

• B. Riley has raised its Q3 2025 earnings per share estimate for Tango Therapeutics to $0.10, a significant increase from the previous estimate of ($0.33).
• Guggenheim increased its price target for Tango Therapeutics from $8.00 to $10.00 and maintained a "buy" rating for the stock.
• Shares of Tango Therapeutics rose by 5.5%, closing at $6.76, reflecting the positive adjustments from analysts and investors.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Investment analysts at B. Riley lifted their Q3 2025 earnings per share estimates for Tango Therapeutics in a research note issued on Monday, August 11th. B. Riley analyst Y. Zhi now expects that the company will earn $0.10 per share for the quarter, up from their prior estimate of ($0.33). The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. B. Riley also issued estimates for Tango Therapeutics' Q4 2025 earnings at ($0.39) EPS and FY2025 earnings at ($1.00) EPS.

Separately, Guggenheim upped their price objective on Tango Therapeutics from $8.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, August 6th.

Tango Therapeutics Stock Up 5.5%

Shares of Tango Therapeutics stock opened at $6.76 on Wednesday. The company has a market cap of $752.12 million, a price-to-earnings ratio of -5.08 and a beta of 1.64. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $12.02. The company's 50 day moving average is $5.70 and its 200 day moving average is $3.23.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35). Tango Therapeutics had a negative return on equity of 79.72% and a negative net margin of 599.11%. The business had revenue of $3.18 million for the quarter, compared to the consensus estimate of $6.41 million.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TNGX. CWM LLC grew its position in Tango Therapeutics by 182.2% in the second quarter. CWM LLC now owns 4,905 shares of the company's stock worth $25,000 after acquiring an additional 3,167 shares during the period. Stonebrook Private Inc. acquired a new stake in Tango Therapeutics in the fourth quarter valued at approximately $34,000. Ameriprise Financial Inc. acquired a new stake in shares of Tango Therapeutics in the 4th quarter valued at $35,000. Dynamic Technology Lab Private Ltd lifted its position in shares of Tango Therapeutics by 139.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company's stock worth $35,000 after purchasing an additional 15,037 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in shares of Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company's stock worth $36,000 after purchasing an additional 1,640 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company's stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.